IL-12 stimulation but not B7 expression increases melanoma killing by patient cytotoxic T lymphocytes (CTL)

Clinical and Experimental Immunology

Volumn 105, Issue 2, 1996, Pages 353-359

  De Wit, D ^a   Flemming, C L ^a   Harris, J D ^a   Palmer, K J ^a   Moore, J S ^b   Gore, M E ^b   Collins, M K L ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Cytotoxic T cell; IL 12; Melanoma

Indexed keywords

B7 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 2;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; PRIORITY JOURNAL;

EID: 0030036095     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.d01-773.x     Document Type: Article

References (57)

1. Boon T, Snick JV, Pel AV et al. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocytemediated cytolysis. J Exp Med 1980; 152:1184-93.
2. Brunner K, MacDonald R, Cerottini J. Quantitation and clonal isolation of cytolytic T lymphocyte precursors selectively infiltrating murine sarcoma virus-induced tumors. J Exp Med 1981; 154:362-73
3. Uyttenhove C, Maryanski J, Boon T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med 1983; 157:1040-52.
4. Boon T. Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherupy. Int J Cancer 1993; 54:177-80.
5. Bruggen P van de, Traversai S, Shenez P et al. A gene encoding an antigen recognised by cytolytic T lymphocytes on a human melanoma. Science 1991; 354:1643-7.
6. Mazzocchi A, Belli F, Mascheroni L et al. Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients. Int J Cancer 1994; 58:330-9.
7. Coulie P, Somville M, Lehmann F et al. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells, Int J Cancer 1992; 50:289-97.
8. Connor J, Bannerji R, Saito S et al. Regression of bladder tumours in mice treated with IL2 gene-modified cells. J Exp Med 1993; 117:1127-34.
9. Fearon E, Pardoll D, Itaya T et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60:397-403.
10. Gansbacher B, Zier K, Daniels B et al. Inlerleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172:1217-24.
11. Porgador A, Gansbacher B, Bannerji R et al. Anti-nietastatic vaccination of tumour-bearing mice with IL2 gene-inserted tumour cells. Int J Cancer 1993; 53:471-7.
12. Russell S, Eccles S, Flemming C et al. Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int J Cancer 1991; 47:244-51.
13. Hock H, Dorsch M, Kunzendorf U et al. Mechanisms of rejection induced by tumor cell-target gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon γ. Proc Natl Acad Sci USA 1993; 90:2774-8.
14. Patel P, Flemming C, Russell S et al. Comparison of the potential therapeutic effects of IL2 or IL4 secretion by a single tumour. Brit J Cancer 1993; 68:295-302.
15. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90:3539-43.
16. Gansbacher B, Bannerji R, Daniels B et al. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990; 50:7820-5.
17. Esumi N, Hunt B, Itaya T et al. Reduced tumourogenicity of murine tumour cells secreting γ-interferon is due to nonspecific host responses and is unrelated to class I major histocompatibility complex expression. Cancer Res 1991; 51:1185-9.
18. Watanabe Y, Kuribayashi K, Miyatake S et al. Exogenous expression of mouse interferon γ-cDNA in mouse neuroblastoma Cl300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA 1989; 86:9456-60.
19. Tahara H, Zeh HJ III. Storkus W et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994; 54:182-9.
20. Tahara H, Lotze M. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Therapy 1995; 2:96-106.
21. Wallich R, Bulbuc N, Hammerling G et al. Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 1985; 315:301-5.
22. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 1995; 181:619-29.
23. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol 1994; 153:421.
24. Ramarathinam L, Castle M, Wu Y et al. T cell costimulation by B7/ BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med 1994; 179:1205-14.
25. + T cells by B7-transfected melanoma cells. Science 1993; 259:368-70.
26. Golumbek P, Lazenby A, Levitsky H et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991; 254:713-7.
27. Patel P, Flemming C, Fisher C et al. Generation of interleukin-2-secreting melanoma cell populations from resected metastatic tumors. Hum Gene Ther 1994; 5:577-84.
28. Immunisation of cancer patients using autologous cancer cells modified by insertion of the gene for interleukin-2. Hum Gene Ther 1992; 3:75-90.
29. Uchiyama A, Boon DSB, Morisaki T et al. Transfection of IL2 gene into human melanoma cells augments cellular immune response. Cancer Res 1993; 53:949-52.
30. Cohen-Haguenauer O. European working group on human gene transfer and therapy, Paris: EDK Press, 1995.
31. Caseinelli N, Foa R, Parmiani G. Active immunization of melastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells. A Phase I II study. Hum Gene Ther 1994; 5:1059-64.
32. Osanto S, Weijl N, Brouwenstijn N et al. Gene therapy of melanoma patients. Gene Therapy 1994; 1:S17.
33. Nabel G, Nabel E, Yang Z-Y et al. Molecular genetic interventions for cancer. Cold Spring Harbor Laboratory, meeting on Gene Therapy 1994; CSH Press, Abstr.:203.
34. + T lymphocytes. J Immunol 1993; 151:2444.
35. Bloom E, Horvath J. Cellular and molecular mechanisms of the IL-12-induced increase in allospecific murine cytolytic T cell activity. J Immunol 1994; 152:4242.
36. Chehimi J, Valiante N, D'Andrea A et al. Enhancing effect of natural killer cell stimulatory factor (NKSF/interleukin-12) on cell-mediated cytotoxicity against tumor-derived and virus-infected cells. Fur J Immunol 1993; 23:1826-30.
37. Brunda M, Luistro L, Warrier R et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178:1223-30.
38. Gately M, Wolitzky A, Quinn P et al. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol 1992; 143:127-42.
39. Manetti R, Parronchi P, Giudizi M et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993; 177:1199-204.
40. Scott P. IL-12: initiation cytokine for cell-mediated immunity. Science 1993; 260:496-7.
41. Chen L, Ashe S, Brady W et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71:1093-102.
42. Henry CW, Dick JW. Separation of gametocytes of L. smithii from whole peripheral turkey blood. Avian Dis 1978; 22:542-6
43. Markowitz D, Goff S, Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virol 1988; 167:400-6.
44. Yokochi T, Holly R, Clark E. B lymphoblast antigen (BB-1) expressed on Epstein - Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas. J Immunol 1982; 128:823-7.
45. Andersson L, Nilsson K, Gahmberg C. K562 - a human erythroleukemic cell line. Int J Cancer 1979; 23:143.
46. Freeman G, Freedman A, Segil J et al. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol 1989; 143:2714-22.
47. Sharrock C, Kaminski E, Man S. Limiting dilution analysis of human T cells: a useful clinical tool. Immunol Today 1990; 11:281-6.
48. Muul L, Gately M. Hydrocortisone suppresses the generation of nonspecific 'anomalous' killers but not specific cytolytic T lymphocytes in human mixed lymphocyte tumor cultures. J Immunol 1984; 132:1202-7.
49. Soiffer R, Robertson M, Murray C et al. Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologie and solid malignancies. Blood 1993; 82:2790-6.
50. Houghton A. Cancer antigens: immune recognition of self and altered self. J Exp Med 1994; 180:1-4.
51. Eynde B van de, Hainaut P, Herin M et al. Presence on a human melanoma of multiple antigens recognised by autologous CTL. Int J Cancer 1989; 44:634-40.
52. Schadendorf D, Moller A, Algermissen B et al. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol 1993; 151:2667-75.
53. Jicha DL, Mule JJ, Rosenberg SA. IL-7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy. J Exp Med 1991; 174:1511-5.
54. Lynch DH, Miller RE. IL-7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo. J Exp Med 1994; 179:31-42.
55. Rabinowich H, Herberman R, Whiteside T. Differential effects of IL12 and IL2 on expression and function of cellular adhesion molecules on purified human natural killer cells. Cell Immunol 1993; 152:481-98.
56. Kubin M, Kamoun M, Trinchieri G. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J Exp Med 1994; 180:211-22.
57. Fearon E, Itaya T, Hunt B et al. Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res 1988; 48:2975-80.